TITLE

Liver Embolization with Trisacryl Gelatin Microspheres (Embosphere) in Patients with Neuroendocrine Tumors

AUTHOR(S)
Granberg, D.; Eriksson, L. -G.; Welin, S.; Kindmark, H.; Janson, E. T.; Skogseid, B.; Öberg, K.; Eriksson, B.; Nyman, R.
PUB. DATE
February 2007
SOURCE
Acta Radiologica;Feb2007, Vol. 48 Issue 2, p180
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: To report our experience of liver embolization with trisacryl gelatin microspheres (Embosphere™) in patients with metastatic neuroendocrine tumors. Material and Methods: Fifteen patients underwent selective embolization of the right or left hepatic artery with Embosphere. One lobe was embolized in seven patients and both lobes, on separate occasions, in eight patients. Seven patients had midgut carcinoids, two had lung carcinoids, one suffered from a thymic carcinoid, and five had endocrine pancreatic tumors. Eight patients suffered from endocrine symptoms, seven of whom had carcinoid syndrome and one WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome. Results: Partial radiological response was seen after eight embolizations (in six different patients), stable disease was observed after 13 embolizations (after three of these, necroses occurred), while radiological progression was noted after only two embolizations. Only two patients experienced a biochemical response. Clinical improvement of carcinoid syndrome was observed after five embolizations. There were no major complications. Fever >38°C was seen after all but four embolizations, and urinary tract infections were diagnosed after eight embolizations. Conclusion: Selective hepatic artery embolization with Embosphere particles is a safe treatment for patients with metastatic neuroendocrine tumors and may lead to partial radiological response as well as symptomatic improvement of disabling endocrine symptoms.
ACCESSION #
24280229

 

Related Articles

  • Is Surgery Indicated for Patients with Symptomatic Nonfunctioning Pancreatic Neuroendocrine Tumor and Unresectable Hepatic Metastases? Ji-Shiang Hung; Ming-Chu Chang; Po-Huang Lee; Yu-Wen Tien // World Journal of Surgery;Dec2007, Vol. 31 Issue 12, p2392 

    Patients with advanced pancreatic neuroendocrine tumor, even in the presence of unresectable hepatic metastases, have survival usually measured in years than in months. Theoretically, we would have reason to resect symptomatic primary pancreatic neuroendocrine tumors from these patients...

  • Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors. Eriksson, John; Stålberg, Peter; Nilsson, Anders; Krause, Johan; Lundberg, Christina; Skogseid, Britt; Granberg, Dan; Eriksson, Barbro; Åkerström, Göran; Hellman, Per // World Journal of Surgery;May2008, Vol. 32 Issue 5, p930 

    Many neuroendocrine tumors (NETs) have a tendency to metastasize to the liver. In case of limited number of metastases, liver surgery or radiofrequency ablation (RFA) may result in apparently total clearance of metastases. However, it is not clear whether such therapy will provide symptom...

  • Metastatic lesions to the liver: Surgical indications and techniques. Tejedor, Luis; Serrablo, Alejandro // Journal of Solid Tumors;Feb2014, Vol. 4 Issue 1, p11 

    Background: Although there is an established agreement on the advantage of liver resection for metastatic colorectal and neuroendocrine tumours, the role of hepatic surgery in patients with liver metastases from non-colorectal and non-neuroendocrine carcinoma is not well defined. In recent...

  • Chromogranin A, a Marker of the Therapeutic Success of Resection of Neuroendocrine Liver Metastases: Preliminary Report. Søndenaa, Karl; Jon Sen; Heinle, Frank; Fjetland, Lars; Gudlaugsson, Einar; Syversen, Unni // World Journal of Surgery;Sep2004, Vol. 28 Issue 9, p890 

    Recent publications indicate that life may be prolonged by surgical debulking of neuroendocrine tumors. A minimum 90% reduction of liver metastases has been suggested to alleviate symptoms of the carcinoid. We have used the tumor marker chromogranin A (CgA) to assess hepatic resection in...

  • Lung carcinoid related Cushing's syndrome: report of three cases and review of the literature. Amer, K. M. A.; Ibrahim, N. B. N.; Forrester-Wood, C. P.; Saad, R. A.; Scanlon, M. // Postgraduate Medical Journal;Jul2001, Vol. 77 Issue 909, p464 

    Three patients with lung carcinoid related Cushing's syndrome (LCRCS) treated at Frenchay Hospital, Bristol between 1984 and 1994 are described. The first patient presented with hyperpigmentation 13 years after bilateral adrenalectomy. The second patient had no recurrence or metastases 14 years...

  • Embolization for the Treatment of Hypervascularized Tumors. Bonomo, Guido; Vigna, Paolo Della; Monfardini, Lorenzo; Orgera, Gianluigi; Orsi, Franco // European Journal of Clinical & Medical Oncology;2010, Vol. 2 Issue 4, p38 

    Hypervascular liver tumors include both hepatocellular carcinoma (HCC) and metastatic lesions from neuroendocrine tumors (NETs). Conspicuity of hepatic tumors on diagnostic imaging studies depends on adequate contrast with normal liver parenchyma. As well demonstrated previously, the hepatic...

  • 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases. Ljungberg, Maria; Westberg, Gunnel; Vikhoff-Baaz, Barbro; Starck, Göran; Bo Wängberg; Ekholm, Sven; Ahlman, Håkan; Forssell-Aronsson, Eva // Acta Radiologica;Dec2012, Vol. 53 Issue 10, p1118 

    Background: It is common to treat patients with metastatic disease from gastrointestinal neuroendocrine (NE) tumors with surgical reduction to prolong survival. This can be combined with hepatic arterial embolization (HAE) and medical treatment to reduce hormonal symptoms. Today there are no...

  • Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Limouris, Georgios S.; Chatziioannou, Achilles; Kontogeorgakos, Dimitrios; Mourikis, Dimitrios; Lyra, Maria; Dimitriou, Panagiotis; Stavraka, Anastasia; Gouliamos, Athanassios; Vlahos, Lambros // European Journal of Nuclear Medicine & Molecular Imaging;Oct2008, Vol. 35 Issue 10, p1827 

    The aim of this study is to evaluate the effectiveness of 111In-DTPA-Phe1-octreotide infusions after selective catheterization of the hepatic artery in inoperable metastasised liver, sst2 receptor-positive neuroendocrine tumours due to the effect of 111In Auger electron emission, minimising in...

  • Hepatic neuroendocrine metastases: chemo- or bland embolization? Pitt, Susan C.; Knuth, Jaime; Keily, James M.; McDermott, John C.; Weber, Sharon M.; Chen, Hebert; Rilling, William S.; Quebbeman, Edward J.; Agarwal, David M.; Pitt, Henry A. // Journal of Gastrointestinal Surgery;Nov2008, Vol. 12 Issue 11, p1951 

    Introduction: Aggressive management of hepatic neuroendocrine (NE) metastases improves symptoms and prolongs survival. Because of the rarity of these tumors, however, the best method for hepatic artery embolization has not been established. We hypothesized that in patients with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics